Themis Medicare Ltd
Themis Medicare Ltd Q4 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY25 Net Revenue: Rs. Q4 FY25 EBITDA: -₹5.78 Cr, down 162% YoY vs.
From Themis Medicare Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Net Revenue: Rs. 71.70 Cr, down 27% YoY from Rs. 97.82 Cr in Q4 FY24 (Page 8).
- Formulation Segment grew 20.41% YoY for FY25 (Page 8).
- Hospital and Trade business revenue grew over 11% and ~39% respectively YoY for FY25 (Page 8).
- API business showed a strong recovery in Q4 FY25 with 115% quarter-on-quarter growth compared to Q3 FY25 (Page 8).
- FY25 full year Net Revenue: Rs. 405.51 Cr, up 6.22% YoY from Rs. 381.76 Cr in FY24 (Page 9).
- The company aspires to grow CAGR of 35% over next 3 years (Page 18).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presenta
- Kopran Ltd (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key investor presentation takeaways from Kopran Ltd's Q4 FY25 investor presentation — and how it ranks against sector peers.
- Fermenta Biotech Ltd (Q4 FY25)
Q4 FY25 Revenue: ₹143.7 crore . Key investor presentation takeaways from Fermenta Biotech Ltd's Q4 FY25 investor presentation — and how it ranks against sector
Frequently Asked Questions
What were Themis Medicare Ltd Q4 FY25 results?
Q4 FY25 Net Revenue: Rs. Q4 FY25 EBITDA: -₹5.78 Cr, down 162% YoY vs.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The investor presentation does not explicitly state any specific capex amounts, capacity expansions, or new plant/project details with associated timelines or statuses.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.